within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX18_Amivantamab;

model Amivantamab
  extends Pharmacolibrary.Drugs.ATC.L.L01FX18;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FX18</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amivantamab is a fully human bispecific monoclonal antibody targeting EGFR and MET receptors. It is used for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations and was approved by the FDA in 2021 for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced non-small cell lung cancer receiving intravenous amivantamab as monotherapy.</p><h4>References</h4><ol><li><p>Haddish-Berhane, N, et al., &amp; Zhou, H (2024). Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer. <i>Clinical pharmacology and therapeutics</i> 115(3) 468â€“477. DOI:<a href=\"https://doi.org/10.1002/cpt.3064\">10.1002/cpt.3064</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37776107/\">https://pubmed.ncbi.nlm.nih.gov/37776107</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Amivantamab;
